Legend Biotech (LEGN) Competitors

$26.69 +1.11 (+4.34%)

As of 11:10 AM Eastern

LEGN vs. GMAB, RGC, ASND, BBIO, and SMMT

Should you be buying Legend Biotech stock or one of its competitors? The main competitors of Legend Biotech include Genmab A/S (GMAB), Regencell Bioscience (RGC), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

How does Legend Biotech compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Genmab A/S currently has a consensus target price of $39.07, indicating a potential upside of 44.87%. Legend Biotech has a consensus target price of $58.31, indicating a potential upside of 118.47%. Given Legend Biotech's higher possible upside, analysts plainly believe Legend Biotech is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.83
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Genmab A/S has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.90B	4.31	$963M	$1.32	20.43
Legend Biotech	$1.03B	4.80	-$296.80M	-$0.80	N/A

Genmab A/S has a net margin of 21.05% compared to Legend Biotech's net margin of -28.86%. Genmab A/S's return on equity of 15.34% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Legend Biotech	-28.86%	-21.93%	-13.21%

In the previous week, Genmab A/S had 1 more articles in the media than Legend Biotech. MarketBeat recorded 10 mentions for Genmab A/S and 9 mentions for Legend Biotech. Genmab A/S's average media sentiment score of 0.70 beat Legend Biotech's score of 0.56 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Legend Biotech on 13 of the 17 factors compared between the two stocks.

How does Legend Biotech compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Legend Biotech (NASDAQ:LEGN) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Regencell Bioscience has a net margin of 0.00% compared to Legend Biotech's net margin of -28.86%. Regencell Bioscience's return on equity of 0.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Legend Biotech	-28.86%	-21.93%	-13.21%

In the previous week, Regencell Bioscience had 26 more articles in the media than Legend Biotech. MarketBeat recorded 35 mentions for Regencell Bioscience and 9 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 0.56 beat Regencell Bioscience's score of -0.01 indicating that Legend Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	2 Positive mention(s)	27 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Legend Biotech	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

Legend Biotech has a consensus target price of $58.31, indicating a potential upside of 118.47%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Legend Biotech is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Regencell Bioscience has higher earnings, but lower revenue than Legend Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Legend Biotech	$1.03B	4.80	-$296.80M	-$0.80	N/A

Summary

Legend Biotech beats Regencell Bioscience on 7 of the 13 factors compared between the two stocks.

How does Legend Biotech compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Ascendis Pharma A/S currently has a consensus target price of $291.50, indicating a potential upside of 21.59%. Legend Biotech has a consensus target price of $58.31, indicating a potential upside of 118.47%. Given Legend Biotech's higher possible upside, analysts plainly believe Legend Biotech is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Ascendis Pharma A/S has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.36	-$258M	$8.67	27.65
Legend Biotech	$1.03B	4.80	-$296.80M	-$0.80	N/A

Ascendis Pharma A/S has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

70.9% of Legend Biotech shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ascendis Pharma A/S has a net margin of 57.87% compared to Legend Biotech's net margin of -28.86%. Ascendis Pharma A/S's return on equity of 0.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Legend Biotech	-28.86%	-21.93%	-13.21%

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Legend Biotech. MarketBeat recorded 12 mentions for Ascendis Pharma A/S and 9 mentions for Legend Biotech. Ascendis Pharma A/S's average media sentiment score of 1.23 beat Legend Biotech's score of 0.56 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Legend Biotech on 14 of the 17 factors compared between the two stocks.

How does Legend Biotech compare to BridgeBio Pharma?

Legend Biotech (NASDAQ:LEGN) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Legend Biotech presently has a consensus target price of $58.31, suggesting a potential upside of 118.47%. BridgeBio Pharma has a consensus target price of $88.19, suggesting a potential upside of 35.68%. Given Legend Biotech's higher probable upside, equities analysts plainly believe Legend Biotech is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
BridgeBio Pharma	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.92

Legend Biotech has higher revenue and earnings than BridgeBio Pharma. Legend Biotech is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	4.80	-$296.80M	-$0.80	N/A
BridgeBio Pharma	$502.08M	25.36	-$724.93M	-$3.74	N/A

Legend Biotech has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Legend Biotech has a net margin of -28.86% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-28.86%	-21.93%	-13.21%
BridgeBio Pharma	-124.42%	N/A	-65.81%

In the previous week, BridgeBio Pharma had 25 more articles in the media than Legend Biotech. MarketBeat recorded 34 mentions for BridgeBio Pharma and 9 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 0.56 beat BridgeBio Pharma's score of 0.35 indicating that Legend Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	10 Very Positive mention(s)	0 Positive mention(s)	15 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BridgeBio Pharma beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Summit Therapeutics?

Legend Biotech (NASDAQ:LEGN) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Summit Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -28.86%. Legend Biotech's return on equity of -21.93% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-28.86%	-21.93%	-13.21%
Summit Therapeutics	N/A	-291.24%	-243.07%

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Legend Biotech has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.25, meaning that its stock price is 225% less volatile than the broader market.

Legend Biotech has higher revenue and earnings than Summit Therapeutics. Legend Biotech is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	4.80	-$296.80M	-$0.80	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

Legend Biotech presently has a consensus target price of $58.31, suggesting a potential upside of 118.47%. Summit Therapeutics has a consensus target price of $27.58, suggesting a potential upside of 47.81%. Given Legend Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Legend Biotech is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Summit Therapeutics	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Summit Therapeutics had 6 more articles in the media than Legend Biotech. MarketBeat recorded 15 mentions for Summit Therapeutics and 9 mentions for Legend Biotech. Summit Therapeutics' average media sentiment score of 1.09 beat Legend Biotech's score of 0.56 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Legend Biotech beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Legend Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LEGN vs. The Competition

Export

Metric	Legend Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.97B	$3.41B	$6.24B	$12.14B
Dividend Yield	N/A	2.25%	2.78%	5.23%
P/E Ratio	-33.57	15.32	20.67	25.38
Price / Sales	4.80	304.64	547.41	75.53
Price / Cash	N/A	56.93	27.81	36.29
Price / Book	4.92	6.83	9.59	6.65
Net Income	-$296.80M	$24.11M	$3.54B	$333.19M
7 Day Performance	-6.39%	-1.58%	-0.45%	-0.55%
1 Month Performance	46.97%	3.84%	5.68%	7.66%
1 Year Performance	-17.58%	70.95%	38.47%	35.65%

Legend Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LEGN Legend Biotech	4.2232 of 5 stars	$26.69 +4.3%	$58.31 +118.5%	-19.0%	$4.97B	$1.03B	N/A	2,965	Earnings Report Gap Down
GMAB Genmab A/S	4.3236 of 5 stars	$27.04 +2.2%	$39.07 +44.5%	+35.0%	$16.49B	$3.72B	17.45	3,029
RGC Regencell Bioscience	0.313 of 5 stars	$27.36 -6.0%	N/A	N/A	$14.40B	N/A	N/A	10	Earnings Report
ASND Ascendis Pharma A/S	4.5639 of 5 stars	$228.71 +3.5%	$291.56 +27.5%	+57.8%	$13.78B	$814.57M	N/A	1,189	Positive News Earnings Report Analyst Upgrade
BBIO BridgeBio Pharma	3.4698 of 5 stars	$68.99 +0.6%	$87.71 +27.1%	+89.3%	$13.42B	$502.08M	N/A	400	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LEGN) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Legend Biotech (LEGN) Competitors

LEGN vs. GMAB, RGC, ASND, BBIO, and SMMT

How does Legend Biotech compare to Genmab A/S?

Summary

How does Legend Biotech compare to Regencell Bioscience?

Summary

How does Legend Biotech compare to Ascendis Pharma A/S?

Summary

How does Legend Biotech compare to BridgeBio Pharma?

Summary

How does Legend Biotech compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Legend Biotech (LEGN) Competitors

LEGN vs. GMAB, RGC, ASND, BBIO, and SMMT

How does Legend Biotech compare to Genmab A/S?

Do analysts rate GMAB or LEGN?

Do institutionals and insiders have more ownership in GMAB or LEGN?

Which has more volatility & risk, GMAB or LEGN?

Which has stronger valuation and earnings, GMAB or LEGN?

Is GMAB or LEGN more profitable?

Does the media refer more to GMAB or LEGN?

Summary

How does Legend Biotech compare to Regencell Bioscience?

Is RGC or LEGN more profitable?

Does the media refer more to RGC or LEGN?

Which has more risk & volatility, RGC or LEGN?

Do analysts recommend RGC or LEGN?

Do insiders & institutionals have more ownership in RGC or LEGN?

Which has preferable valuation & earnings, RGC or LEGN?

Summary

How does Legend Biotech compare to Ascendis Pharma A/S?

Do analysts recommend ASND or LEGN?

Which has preferable valuation & earnings, ASND or LEGN?

Which has more risk & volatility, ASND or LEGN?

Do insiders & institutionals have more ownership in ASND or LEGN?

Is ASND or LEGN more profitable?

Does the media refer more to ASND or LEGN?

Summary

How does Legend Biotech compare to BridgeBio Pharma?

Do analysts prefer LEGN or BBIO?

Which has higher earnings and valuation, LEGN or BBIO?

Which has more risk & volatility, LEGN or BBIO?

Do institutionals & insiders have more ownership in LEGN or BBIO?

Is LEGN or BBIO more profitable?

Does the media prefer LEGN or BBIO?

Summary

How does Legend Biotech compare to Summit Therapeutics?

Is LEGN or SMMT more profitable?

Do insiders and institutionals have more ownership in LEGN or SMMT?

Which has more volatility and risk, LEGN or SMMT?

Which has stronger earnings & valuation, LEGN or SMMT?

Do analysts rate LEGN or SMMT?

Does the media favor LEGN or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools